Skip to content

A Study of Tetanus Antibody of Healthy Adults

A Prospective Study of Tetanus Antibody Protective Efficacy in Healthy Populations in Beijing

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07724379
Acronym
tetanus
Enrollment
2009
Registered
2026-07-24
Start date
2025-05-04
Completion date
2026-05-15
Last updated
2026-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tetanus

Keywords

Healthy Adults, Vaccination, Protective Efficacy, Observational Study, TQS, tetanus

Brief summary

The goal of this observational study is to learn about antibody level of tetanus of adults in high-income city of china. The main question it aims to answer is: 1. Analysis of tetanus antibody distribution across different age groups 2. Evaluation of the TQS method for determining antibody status 3. Correlation between primary vaccination history and tetanus antibody concentrations Blood samples were voluntarily provided by adult healthy participants for tetanus antibody analysis over a continuous collection period of more than one year.

Interventions

None listed

Sponsors

Peking University First Hospital
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Voluntarily sign the informed consent form; * Be aged 18 years or older; * Be willing to provide a blood sample for biochemical testing

Exclusion criteria

* Receipt of immunoglobulin, blood, or blood products within 6 months prior to enrollment; * Refusal to provide tetanus vaccination history (including vaccination records, CDC vaccine administration registry, or subject's recall); * Individuals with recent tetanus vaccination (within 5 years), acute illness, pregnancy, or immunosuppressive conditions will be excluded

Design outcomes

Primary

MeasureTime frameDescription
Tetanus Antibody LevelBaseline (single blood draw at enrollment)Single blood draw

Secondary

MeasureTime frameDescription
tetanus antibody level by TQS/mTQS methodBaseline (single blood draw at enrollment)at baseline

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 25, 2026